Latest news with #Drug


New York Post
16 hours ago
- Business
- New York Post
JM Smucker becomes latest food manufacturer to remove artificial colors from popular brands
The J.M. Smucker Co. joined a growing list of food giants that are pledging to eliminate FD&C artificial dyes from its products within the next two years, aligning with the Trump administration's goals of removing artificial colors from the nation's food supply. Smucker's said this commitment, announced Friday, will affect its sugar-free fruit spreads and ice cream toppings as well as certain products from its Hostess brand portfolio. The company also said it's working with its distribution partners to no longer sell products with FD&C colors to K-12 schools by the 2026 – 2027 school year. Smucker's, whose family of brands includes Folgers, Dunkin', Café Bustelo, Jif, Uncrustables, Smucker's and Hostess, said most of its consumer foods are already free of FD&C colors, including a majority of its products currently available to K-12 schools. The company has previously removed high-fructose corn syrup from its Uncrustables sandwiches and introduced fruit spreads featuring ingredients from all natural sources as well as reduced sugar options. 'Our commitment to remove FD&C colors from our sugar-free fruit spreads, ice cream toppings, and sweet baked goods products represents the latest example of our desire to evolve and our ability to continue to innovate to deliver on the expectations of our consumers,' J.M. Smucker CEO Mark Smucker said. The artifical dyes are known as FD&C colors and labeled as such on packages because the color additive is approved by the FDA for use in food, drugs, and cosmetics. 3 The J.M. Smucker Co. is the latest food giant to remove artificial dyes from its products. Bloomberg News They are subject to a strict system of approval under the Federal Food, Drug, and Cosmetic Act (FD&C Act). Last week, General Mills and Kraft Heinz issued their own commitments to remove all artificial dyes from their respective U.S. portfolios by the end of 2027. PepsiCo CEO Ramon Laguarta said during an April 24 conference call that the company will reduce artificial ingredients and has already begun doing so, while McCormick, which manufactures and distributes spices, seasoning mixes, condiments and other flavoring products, told analysts during its earnings call in March that it has been working with restaurants and foodmakers to reformulate products to remove certain ingredients like food dyes. Earlier this year, the Food and Drug Administration (FDA) announced plans to launch a stronger review process for food chemicals already on the market to ensure the nation's food supply is more transparent and ensure the safety of chemicals in food. 3 Sugar-free fruit spreads and ice cream toppings will be affected, though certain dyes in other products will still be in use, approved by the FDA. AP Health and Human Services Secretary Robert F. Kennedy Jr. previously said that 'some food producers have been feeding Americans petroleum-based chemicals without their knowledge or consent' for too long. He also claimed that these 'poisonous compounds offer no nutritional benefit and pose real, measurable dangers to our children's health and development.' Kennedy and the FDA announced in April a series of new measures to phase out all petroleum-based synthetic dyes from the nation's food supply. 3 The company plans to remove the dyes from its products within the next two years. Getty Images Kennedy noted that this effort would need voluntary support from food manufacturers, but that the 'industry has voluntarily agreed' to do so. The FDA has approved seven certified color additives for use in food, six of which were approved by 1931. Now, it's working with the industry to eliminate FD&C Green No. 3, FD&C Red No. 40, FD&C Yellow No. 5, FD&C Yellow No. 6, FD&C Blue No. 1 and FD&C Blue No. 2 from the food supply by 2027. The FDA in January revoked the authorization for the use of Red No. 3, also known as erythrosine, in food and ingested drugs over concerns that it has been shown to cause cancer in animals.


Leaders
a day ago
- Health
- Leaders
In Photos: GCC Marks the International Day Against Drug Abuse, Illicit Trafficking
Jasem Mohamed Albudaiwi, Secretary General of the Gulf Cooperation Council (GCC), emphasized the utmost priority given by GCC member states to combating drugs, explaining that this commitment stems from their belief in protecting societies and enhancing the security and safety of citizens. During the celebration of the International Day Against Drug Abuse and the Gulf Anti-Drug Week, Albudaiwi addressed attendees, including representatives from the Ministries of Interior and relevant officials from GCC member states. He remarked, 'This occasion embodies the commitment of the GCC member states to continue collective and joint Gulf action.' A Unified Strategy for Drug Control Albudaiwi highlighted the Gulf Strategy for Combating Drugs (2025 – 2028) as a comprehensive framework. He explained, 'This strategy is based on key pillars, including reducing the supply and demand for drugs.' The strategy aims to dry up sources of drugs while promoting alternative development and enhancing the Gulf legislative system. He added, 'Combating drugs is a collective responsibility that requires integrated action, sustained effort, and close cooperation.' This approach involves collaboration between governments, societies, and individuals to effectively address drug-related issues. Albudaiwi underscored the vital role of families and society in drug prevention. He stated, 'They constitute the first line of defense against drugs through conscious upbringing, open dialogue, and continuous care.' Schools, media, religious leaders, and civil society institutions also play crucial roles in spreading awareness. He further emphasized, 'The family has a significant and valuable role in providing emotional and social support.' This support creates a stable environment that boosts the self-confidence of recovering individuals and encourages them to rebuild their lives. Supporting Recovery and Reintegration The Secretary General affirmed the importance of integrating recovering addicts into society. He noted, 'The GCC states have been keen to establish hospitals, centres, and institutions dedicated to this matter.' These facilities provide treatment and rehabilitation programs, ensuring active participation in society. Albudaiwi expressed pride in the cooperation with strategic partners across GCC member states, saying, 'We are keen to bolster these partnerships to ensure coordination and integration at the regional and international levels.' This collaboration aims to build safe, drug-free societies that protect future generations from the dangers of drug abuse. Short link : Post Views: 16
Yahoo
4 days ago
- Business
- Yahoo
Leerink Partners Reiterates a Buy Rating on Disc Medicine (IRON) With an $85 Price Target
Disc Medicine, Inc. (NASDAQ:IRON) is one of the 13 Small Cap Stocks Analysts Are Bullish On. In a report released on June 16, Thomas Smith from Leerink Partners maintained a Buy rating on Disc Medicine, Inc. (NASDAQ:IRON) with a price target of $85.00. The analyst based the rating on the company's positive developments in its hematology-focused pipeline. A scientist in a laboratory setting examining a sample of blood with a microscope. Smith stated that Disc Medicine, Inc. (NASDAQ:IRON) is set to submit a New Drug Application for bitopertin, an oral GlyT1 inhibitor, that is anticipated to leverage an accelerated approval pathway. The HELIOS long-term extension study reported positive initial data supporting this progress, as it suggested improvements in live function, sustained reductions in PPIX, and a clean safety profile. Disc Medicine, Inc. (NASDAQ:IRON) is also participating in ongoing trials, such as the Phase 2 RALLY-MF trial and the Phase 1b MF anemia trial, which have shown positive results with improved biomarker responses. The analyst considers this another positive factor supporting the buy rating. Disc Medicine, Inc. (NASDAQ:IRON) is a clinical-stage biopharmaceutical company that discovers, develops, and commercializes treatments for hematologic diseases. While we acknowledge the potential of IRON as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money. Disclosure: None. Errore nel recupero dei dati Effettua l'accesso per consultare il tuo portafoglio Errore nel recupero dei dati Errore nel recupero dei dati Errore nel recupero dei dati Errore nel recupero dei dati
Yahoo
4 days ago
- Business
- Yahoo
Quoin Pharmaceuticals Announces FDA Grants Rare Pediatric Disease Designation for QRX003 in Netherton Syndrome
ASHBURN, Va., June 24, 2025 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) ('Quoin' or the 'Company'), a late clinical-stage specialty pharmaceutical company focused on rare and orphan diseases, today announced that the U.S. Food and Drug Administration (FDA) has granted Rare Pediatric Disease (RPD) Designation for the Company's lead asset, QRX003, for the treatment of Netherton Syndrome. The designation reinforces the potential of QRX003 as a therapeutic candidate for a profoundly underserved pediatric population. It follows earlier regulatory recognition by the European Medicines Agency (EMA), which granted Orphan Drug Designation to QRX003 in May 2025. 'We are very pleased to announce the receipt of Rare Pediatric Disease Designation for QRX003 for Netherton Syndrome, a severe and underserved genetic disease,' said Dr. Michael Myers, Chief Executive Officer of Quoin Pharmaceuticals. 'The Quoin team is fully focused on completing our pivotal clinical studies and advancing QRX003 towards a New Drug Application as the first potential treatment for this terrible disease. We are highly encouraged by the promising efficacy data and clean safety profile seen to date.' The FDA's Rare Pediatric Disease Designation program is intended to encourage the development of new therapies for serious and life-threatening diseases that primarily affect individuals under 18 years of age. If a New Drug Application (NDA) for QRX003 is approved, upon reauthorization of the program Quoin may be eligible to receive a Priority Review Voucher (PRV), which can be redeemed to receive priority review for another marketing application or may be sold or transferred. About Netherton Syndrome in ChildrenNetherton Syndrome is a rare genetic disorder affecting approximately 1 in 200,000 newborns worldwide. Symptoms typically present at birth or in early infancy and persist throughout life. Affected infants often require prolonged hospitalization due to severe skin inflammation, dehydration, and increased risk of infection. The condition can be challenging to diagnose early, as it may resemble other dermatological or immunological disorders. Mortality in infancy is estimated at 10 to 20 percent, underscoring the serious clinical burden associated with the disease. About Quoin Pharmaceuticals Pharmaceuticals Ltd. is a late clinical-stage specialty pharmaceutical company focused on developing and commercializing therapeutic products that treat rare and orphan diseases. We are committed to addressing unmet medical needs for patients, their families, communities and care teams. Quoin's innovative pipeline comprises four products in development that collectively have the potential to target a broad number of rare and orphan indications, including Netherton Syndrome, Peeling Skin Syndrome, Palmoplantar Keratoderma, Scleroderma, Epidermolysis Bullosa and others. For more information, visit: or LinkedIn for updates. Cautionary Note Regarding Forward Looking StatementsThe Company cautions that statements in this press release that are not a description of historical facts are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements may be identified by the use of words referencing future events or circumstances such as 'expect,' 'intend,' 'plan,' 'anticipate,' 'believe,' 'look forward to,' and 'will,' among others. All statements that reflect the Company's expectations, assumptions, projections, beliefs, or opinions about the future, other than statements of historical fact, are forward-looking statements, including, without limitation, statements relating to: potential of QRX003 as a therapeutic candidate for a profoundly underserved pediatric population, completing the Company's pivotal clinical studies, advancing QRX003 towards a New Drug Application as the first potential treatment for Netherton Syndrome, if a New Drug Application for QRX003 is approved, upon reauthorization of the program, Quoin may be eligible to receive a Priority Review Voucher, and Quoin's belief that its products in development collectively have the potential to target a broad number of rare and orphan indications, including Netherton Syndrome, Peeling Skin Syndrome, Palmoplantar Keratoderma, Scleroderma, Epidermolysis Bullosa and others. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. These forward-looking statements are based upon the Company's current expectations and involve assumptions that may never materialize or may prove to be incorrect. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of various risks and uncertainties including, but not limited to, the Company's ability to pursue its regulatory strategy; the Company's ability to obtain regulatory approvals for commercialization of product candidates or to comply with ongoing regulatory requirements; the Company's ability to complete clinical trials on time and achieve desired results and benefits as expected; and other factors discussed in the Company's Annual Report on Form 10-K for the year ended December 31, 2024 and in other filings the Company has made and may make with the SEC in the future. One should not place undue reliance on these forward-looking statements, which speak only as of the date on which they were made. The Company undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made, except as may be required by law. For further information, contact: Quoin Pharmaceuticals Myers, Ph.D., CEOmmyers@ Investor RelationsPCG AdvisoryJeff Ramsonjramson@ 863-6341Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data


Economic Times
4 days ago
- Health
- Economic Times
Trump administration's MAHA initiative making your kitchen healthier
Major food giants commit to cleaner ingredients General Mills announced that 85% of its U.S. portfolio is already free of FD&C (Food, Drug, and Cosmetic Act-approved) artificial dyes, with plans to remove the remaining dyes by 2027. Their cereals, including well-known brands like Lucky Charms and Trix, will be reformulated by summer 2026. Kraft Heinz targets beverages and desserts, including brands like Crystal Light, Kool-Aid, and Jell-O, which currently contain artificial dyes. The company also confirmed it will not launch new U.S. products containing these dyes. PepsiCo aims to remove artificial colors from snack brands such as Lay's and Tostitos by the end of this year. In-N-Out Burger has replaced artificial colors with natural ingredients like turmeric and beta-carotene in several menu items and is working on healthier ingredient swaps for ketchup and fries. Why the push? The health risks of artificial dyes Live Events Provide no nutritional benefit. Pose measurable risks to children's health and development. Have been included in foods without consumers' knowledge or consent. (You can now subscribe to our (You can now subscribe to our Economic Times WhatsApp channel The Trump administration's Make America Healthy Again (MAHA) initiative is driving a transformation in the U.S. food industry by targeting harmful artificial dyes and chemicals commonly found in popular products. This unprecedented government-industry collaboration has already secured commitments from major food companies to reformulate iconic brands, removing synthetic colors linked to health risks, especially in nearly 70% of American children's calories coming from ultra-processed foods laden with these additives, MAHA aims to reduce chronic diseases like obesity , diabetes, and neurodevelopmental disorders by making everyday foods safer and more a result, kitchens across the country are poised to become healthier, reflecting a bold new era of food transparency and public health a landmark push aligned with MAHA's goals, food industry leaders like General Mills and Kraft Heinz have pledged to eliminate all artificial colors from their U.S. product lines by the end of 2027. These commitments follow earlier moves by companies such as PepsiCo , McCormick, and fast-food chains like In-N-Out Burger and Steak 'n Shake, which have already begun removing synthetic dyes and replacing them with natural and Human Services Secretary Robert F. Kennedy Jr., a key proponent of the MAHA initiative, has been vocal about the dangers of petroleum-based artificial colors. He argues these compounds:The FDA has responded by intensifying its review of food chemicals and announcing plans to phase out several synthetic dyes, including FD&C Green No. 3, Red No. 40, Yellow No. 5, and others by the end of next year. The agency revoked authorization for Red No. 3 earlier this year due to cancer concerns observed in animal reformulation trend not only benefits public health but also aligns with growing consumer demand for transparency and cleaner labels. Surveys show that a majority of Americans prefer foods with natural ingredients and fewer synthetic additives.